Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivities01:30

Hypersensitivities

Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Vaccinations01:51

Vaccinations

Overview
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Legends of Allergy and Immunology: Werner Pichler.

Allergy·2025
Same author

Anaphylaxis in a Swiss university emergency department: clinical characteristics and supposed triggers.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2024
Same author

New light on an old syndrome: Role of Api g 7 in mugwort pollen-related celery allergy.

The Journal of allergy and clinical immunology·2024
Same author

Autoimmunity and immunodeficiency associated with monoallelic LIG4 mutations via haploinsufficiency.

The Journal of allergy and clinical immunology·2023
Same author

Use of epinephrine in anaphylaxis: a retrospective cohort study at a Swiss university emergency department.

Swiss medical weekly·2023
Same author

Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS).

Allergo journal international·2022
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Vaccine hypersensitivity--update and overview.

Philipp J Fritsche1, Arthur Helbling, Barbara K Ballmer-Weber

  • 1Allergy Unit, Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. Philipp.Fritsche@usz.ch

Swiss Medical Weekly
|March 30, 2010
PubMed
Summary
This summary is machine-generated.

Vaccine adverse events are rare, with serious allergic reactions occurring in approximately 1 in 1.5 million doses. Accurate diagnosis and management are crucial for patients experiencing suspected immediate-type reactions to vaccines.

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
05:44

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

Published on: December 9, 2022

Related Experiment Videos

Last Updated: Jun 14, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Murine Model of Epicutaneously-Induced Immunomodulation
09:07

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
05:44

A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis

Published on: December 9, 2022

Area of Science:

  • Immunology
  • Vaccinology
  • Allergology

Background:

  • Public concern regarding vaccine reactions is common.
  • Reported vaccine-induced adverse events occur at low rates, generally between 4.8-83.0 per 100,000 doses.
  • True allergic reactions to routine vaccines are estimated between 1 in 500,000 to 1 in 1,000,000 doses.

Purpose of the Study:

  • To analyze the incidence and nature of adverse events following vaccination.
  • To clarify the frequency of true allergic reactions and anaphylaxis to vaccines.
  • To outline diagnostic and management strategies for suspected immediate-type hypersensitivity reactions to vaccines.

Main Methods:

  • Review of reported vaccine-induced adverse events.
  • Estimation of the incidence of allergic reactions and anaphylaxis.
  • Discussion of diagnostic algorithms for suspected vaccine allergy.

Main Results:

  • Most vaccine reactions are localized at the injection site due to non-specific inflammatory responses.
  • Serious allergic reactions, including anaphylaxis, are rare, occurring at approximately 1 per 1,500,000 doses.
  • The rate of serious allergic reactions may be higher if vaccine formulations contain allergens like gelatin or egg proteins.

Conclusions:

  • Adverse events following vaccination are infrequent, and severe allergic reactions are exceptionally rare.
  • Accurate diagnostic evaluation and established algorithms are essential for managing patients with suspected immediate-type reactions.
  • Informed decisions regarding revaccination can be made based on precise diagnosis and patient history.